Bruker Corporation $BRKR Shares Sold by Bank of America Corp DE

Key Points

• Bank of America reduced its Bruker stake by 3.2% in the first quarter, selling 30,371 shares and retaining 933,596 shares valued at approximately $33.7 million. Institutional investors collectively own 79.52% of BRKR.
• Analyst sentiment remains positive: Bruker has a consensus rating of “Moderate Buy” and an average price target of $56.64, with JPMorgan and Barclays recently raising their targets.
• Bruker’s latest quarterly earnings beat expectations, with EPS of $0.49 versus the $0.38 consensus, while revenue rose 5.2% year over year to $838.5 million. The company issued fiscal 2026 EPS guidance of $2.10–$2.15.

Bank of America Corp DE cut its holdings in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 3.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 933,596 shares of the medical research company's stock after selling 30,371 shares during the quarter. Bank of America Corp DE owned about 0.61% of Bruker worth $33,721,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in BRKR. Orbis Allan Gray Ltd increased its position in shares of Bruker by 5.4% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company's stock worth $702,256,000 after acquiring an additional 761,258 shares in the last quarter. State Street Corp lifted its holdings in shares of Bruker by 2.5% in the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company's stock worth $180,700,000 after purchasing an additional 91,706 shares during the last quarter. AQR Capital Management LLC lifted its position in Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Sculptor Capital LP boosted its position in Bruker by 9.0% during the 1st quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock worth $118,112,000 after acquiring an additional 270,000 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Bruker by 2,963.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company's stock worth $111,488,000 after purchasing an additional 2,289,269 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. raised their target price on Bruker from $55.00 to $65.00 and gave the company an "overweight" rating in a research note on Monday, June 8th. Stifel Nicolaus set a $50.00 price objective on Bruker in a research note on Wednesday, August 5th. Barclays lifted their target price on shares of Bruker from $53.00 to $60.00 and gave the company an "overweight" rating in a research note on Wednesday, June 24th. Wall Street Zen raised shares of Bruker from a "hold" rating to a "buy" rating in a research report on Saturday, May 9th. Finally, Zacks Research upgraded Bruker from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, Bruker currently has a consensus rating of "Moderate Buy" and an average target price of $56.64.

Bruker Stock Performance

Shares of BRKR stock opened at $57.70 on Friday. The stock has a 50-day moving average of $58.36 and a 200-day moving average of $47.05. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The stock has a market cap of $8.79 billion, a PE ratio of -82.43, a price-to-earnings-growth ratio of 1.77 and a beta of 1.28. Bruker Corporation has a one year low of $28.53 and a one year high of $65.30.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million for the quarter, compared to analysts' expectations of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source